Bortezomib Followed by a Phase I Study of Bortezomib in Combination With High-Dose Melphalan as a Preparative Regimen for Hematopoietic Cell Transplants in Patients With Primary Refractory Multiple Myeloma or Plasma Cell Leukemia

Authors :: Taiga Nishihori
Joseph Pidala
V. Oliviera
Claudio Anasetti
K. Shain
J. Raychaudhuri
J.L. Ochoa-Bayona
D.-T. Chen
C.M. Simonelli
Todd J. Alekshun
Jongphil Kim
W. Fulp
Daniel M. Sullivan
B. Maddox
Melissa Alsina
D.N. Yarde
Mohamed A. Kharfan-Dabaja
Source :: Biology of Blood and Marrow Transplantation. 17(2):S200-S201
Publication Year :: 2011
Publisher :: Elsevier BV, 2011.

Subjects :: Plasma cell leukemia
Transplantation
Hematopoietic cell
business.industry
Bortezomib
High dose melphalan
Refractory Multiple Myeloma
Hematology
medicine.disease
Phase i study
medicine
Cancer research
In patient
business
Preparative Regimen
medicine.drug

Full Text Access

Tools